Call Us: +233 362 194 325 - E-mail: info@tajdearobpharma.com

Product

Therapeutic Category

Placeholder

PLOGRYL®

PLOGRYL, proven to help protect against future heart attack or stroke.


Brand Name

PLOGRYL®


Packing

30,100


Therapeutic Category

Antihypertensive


Storage


adobe-pdf-logoProduct Insert(PIL)

adobe-pdf-logoPrescribing Information(SPC)


Product Description

Product Overview


COMPOSITION :

Plogryl…75mg
Each film-coated tablet contains:
Clopidogrel (as bisulfate) …… 75 mg

PLOGRYL® (clopidogrel bisulfate): Help prevent Clot formation for …
PLOGRYL, proven to help protect against future heart attack or stroke. Click for safety and prescribing information.

PLOGRYL helps protect you
against a future heart attack or stroke

If you have had one clot-related event-a heart attack, heart-related chest pain, or stroke -you are at higher risk of another clot-related event. If you have been diagnosed with Peripheral Artery Disease (P.A.D., known as poor circulation in the legs), you are also at higher risk of a heart attack or stroke.

PLOGRYL helps keep platelets in the blood from sticking together and forming clots- the direct cause of most heart attacks and strokes. With its effectiveness proven and safety profile supported by 4 large clinical studies with 81,000 patients, PLOGRYL is the #1 prescription
antiplatelet medicine.

Remember, your doctor is the single best source of information regarding your health.
Please consult your doctor if you have any questions about your health or your medicine.

DESCRIPTION :

PLOGRYL (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Chemically it is methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate sulfate (1:1). The empirical formula of clopidogrel bisulfate is C16H16ClNO2S•H2SO4 and its molecular weight is 419.9.

The structural formula is as follows:

Clopidogrel bisulfate is a white to off-white powder. It is practically insoluble in water at neutral pH but freely soluble at pH 1. It also dissolves freely in methanol, dissolves sparingly in methylene chloride, and is practically insoluble in ethyl ether. It has a specific optical rotation of about +56°.

PLOGRYL for oral administration is provided as either pink, round, biconvex, debossed, film-coated tablets containing 97.875 mg of clopidogrel bisulfate which is the molar equivalent of 75 mg of clopidogrel base or pink, oblong, debossed film-coated tablets containing 391.5 mg of clopidogrel bisulfate which is the molar equivalent of 300 mg of clopidogrel base.

Each tablet contains hydrogenated castor oil, hydroxypropylcellulose, mannitol, microcrystalline cellulose and polyethylene glycol 6000 as inactive ingredients. The pink film coating contains ferric oxide, hypromellose 2910, lactose monohydrate, titanium dioxide and triacetin. The tablets are polished with Carnauba wax.

CLINICAL PHARMACOLOGY :

Mechanism of Action and Pharmacodynamic Properties

Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation. A variety of drugs that inhibit platelet function have been shown to decrease morbid events in people with established cardiovascular atherosclerotic disease as evidenced by stroke or transient ischemic attacks, myocardial infarction, unstable angina or the need for vascular bypass or angioplasty. This indicates that platelets participate in the initiation and/or evolution of these events and that inhibiting platelet function can reduce the event rate.

Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby

inhibiting platelet aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.

Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other drugs, not all patients will have adequate platelet inhibition.

Dose dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of PLOGRYL. Repeated doses of 75 mg PLOGRYL per day inhibit ADP-induced platelet aggregation on the first day, and inhibition reaches steady state between Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg PLOGRYL per day was between 40% and 60%. Platelet aggregation and bleeding time gradually return to baseline values after treatment is discontinued, generally in about 5 days.

Back to Top
Taj Dearob Pharmaceuticals is an Ghana based pharmaceutical company that markets a broad range of innovative therapeutic medicines including UK Generics, high-end Oncology products, more info.